Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 358

1.

Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD.

Katzenschlager R, Head J, Schrag A, Ben-Shlomo Y, Evans A, Lees AJ; Parkinson's Disease Research Group of the United Kingdom.

Neurology. 2008 Aug 12;71(7):474-80. doi: 10.1212/01.wnl.0000310812.43352.66. Epub 2008 Jun 25.

PMID:
18579806
2.

Ten-year follow-up of three different initial treatments in de-novo PD: a randomized trial.

Lees AJ, Katzenschlager R, Head J, Ben-Shlomo Y.

Neurology. 2001 Nov 13;57(9):1687-94.

PMID:
11706112
5.

Treatment of Parkinson's disease: levodopa as the first choice.

Katzenschlager R, Lees AJ.

J Neurol. 2002 Sep;249 Suppl 2:II19-24. Review.

PMID:
12375059
6.

Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease.

Parkinson Study Group CALM Cohort Investigators.

Arch Neurol. 2009 May;66(5):563-70. doi: 10.1001/archneur.66.1.nct90001.

PMID:
19433655
8.

Effect of selegiline on mortality in patients with Parkinson's disease: a meta-analysis.

Olanow CW, Myllylä VV, Sotaniemi KA, Larsen JP, Pålhagen S, Przuntek H, Heinonen EH, Kilkku O, Lammintausta R, Mäki-Ikola O, Rinne UK.

Neurology. 1998 Sep;51(3):825-30.

PMID:
9748034
9.

Early addition of selegiline to L-Dopa treatment is beneficial for patients with Parkinson disease.

Mizuno Y, Kondo T, Kuno S, Nomoto M, Yanagisawa N.

Clin Neuropharmacol. 2010 Jan-Feb;33(1):1-4. doi: 10.1097/WNF.0b013e3181bbf45c.

PMID:
19935410
11.

Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial.

Holloway RG, Shoulson I, Fahn S, Kieburtz K, Lang A, Marek K, McDermott M, Seibyl J, Weiner W, Musch B, Kamp C, Welsh M, Shinaman A, Pahwa R, Barclay L, Hubble J, LeWitt P, Miyasaki J, Suchowersky O, Stacy M, Russell DS, Ford B, Hammerstad J, Riley D, Standaert D, Wooten F, Factor S, Jankovic J, Atassi F, Kurlan R, Panisset M, Rajput A, Rodnitzky R, Shults C, Petsinger G, Waters C, Pfeiffer R, Biglan K, Borchert L, Montgomery A, Sutherland L, Weeks C, DeAngelis M, Sime E, Wood S, Pantella C, Harrigan M, Fussell B, Dillon S, Alexander-Brown B, Rainey P, Tennis M, Rost-Ruffner E, Brown D, Evans S, Berry D, Hall J, Shirley T, Dobson J, Fontaine D, Pfeiffer B, Brocht A, Bennett S, Daigneault S, Hodgeman K, O'Connell C, Ross T, Richard K, Watts A; Parkinson Study Group.

Arch Neurol. 2004 Jul;61(7):1044-53. Erratum in: Arch Neurol. 2005 Mar;62(3):430.

PMID:
15262734
12.
13.
14.

Selegiline as the primary treatment of Parkinson's disease--a long-term double-blind study.

Myllylä VV, Sotaniemi KA, Hakulinen P, Mäki-Ikola O, Heinonen EH.

Acta Neurol Scand. 1997 Apr;95(4):211-8.

PMID:
9150811
15.

The Parkinson-Control study: a 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease.

Castro-Caldas A, Delwaide P, Jost W, Merello M, Williams A, Lamberti P, Aguilar M, Del Signore S, Cesaro P; Parkinson-Control Study Group.

Mov Disord. 2006 Apr;21(4):500-9.

PMID:
16267842
16.

Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa.

Hauser RA, Rascol O, Korczyn AD, Jon Stoessl A, Watts RL, Poewe W, De Deyn PP, Lang AE.

Mov Disord. 2007 Dec;22(16):2409-17.

PMID:
17894339
17.

Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial.

Shoulson I, Oakes D, Fahn S, Lang A, Langston JW, LeWitt P, Olanow CW, Penney JB, Tanner C, Kieburtz K, Rudolph A; Parkinson Study Group.

Ann Neurol. 2002 May;51(5):604-12.

PMID:
12112107
18.

Bromocriptine versus levodopa in early Parkinson's disease.

Ramaker C, van Hilten JJ.

Cochrane Database Syst Rev. 2000;(3):CD002258. Review. Update in: Cochrane Database Syst Rev. 2007;(4):CD002258.

PMID:
10908538
20.

Controversies in the therapy of Parkinson's disease.

Fahn S.

Adv Neurol. 1996;69:477-86. Review.

PMID:
8615168

Supplemental Content

Support Center